OTCMKTS:DNPUF Sumitomo Pharma (DNPUF) Stock Price, News & Analysis $9.79 0.00 (0.00%) As of 10/15/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartNews and Trends About Sumitomo Pharma Stock (OTCMKTS:DNPUF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sumitomo Pharma alerts:Sign Up Key Stats Today's Range$9.79▼$9.7950-Day Range$8.41▼$10.0152-Week Range$8.41▼$19.20VolumeN/AAverage Volume1,341 shsMarket CapitalizationN/AP/E Ratio0.17Dividend Yield146.79%Price TargetN/AConsensus RatingN/A Company Overview Sumitomo Pharma Co., Ltd. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. Its activities focus primarily on central nervous system disorders, including psychiatric and neurological conditions, as well as oncology, metabolic diseases and other areas of unmet medical need. The company’s portfolio has included medicines for schizophrenia, bipolar disorder, depression and Parkinson’s disease, along with treatments in other specialty-care categories. Sumitomo Pharma also conducts research in regenerative medicine and cell therapy, including programs intended to address serious neurological diseases. Headquartered in Osaka, Japan, the company serves patients and healthcare providers in Japan and international markets through subsidiaries, partnerships and regional operations. Sumitomo Pharma was formed in 2005 through the merger of Dainippon Pharmaceutical and Sumitomo Pharmaceuticals and adopted its current name in 2022.AI Generated. May Contain Errors. Read More Receive DNPUF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sumitomo Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DNPUF Stock News HeadlinesSumitomo Pharma Rejects Short-Seller Allegations, Stands by Audited AccountsAugust 4, 2026 | tipranks.comNew Data from Sumitomo Pharma America at AUA 2026 Highlight Efficacy of Vibegron in Men Aged 75 and Older with Overactive Bladder and BPHMay 18, 2026 | businesswire.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.October 16 at 1:00 AM | Profits Run (Ad)Sumitomo Pharma Co., Ltd. GAAP EPS of ¥268.99, revenue of ¥453.29BMay 13, 2026 | seekingalpha.comSumitomo Pharma Profit Jumps on U.S. Asset Transfer and Asian Stake SaleMay 12, 2026 | tipranks.comSumitomo Pharma Launches Major Share Offering to Strengthen Financial BaseApril 8, 2026 | tipranks.comSumitomo Pharma to Book ¥48.3 Billion Dividend as Non-Operating Income With No Group Profit ImpactMarch 25, 2026 | tipranks.comSumitomo Pharma shares plunge nearly 16% despite greenlight for Parkinson's treatmentFebruary 20, 2026 | cnbc.comSee More Headlines DNPUF Stock Analysis - Frequently Asked Questions How have DNPUF shares performed this year? Sumitomo Pharma's stock was trading at $14.36 at the start of the year. Since then, DNPUF stock has decreased by 31.8% and is now trading at $9.79. How do I buy shares of Sumitomo Pharma? Shares of DNPUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today10/16/2026Next Earnings (Estimated)10/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:DNPUF CIKN/A Webwww.ds-pharma.com Phone81 6 6203 5321FaxN/AEmployees6,250Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio0.17 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (OTCMKTS:DNPUF) was last updated on 10/15/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredSpaceX minted 4400 millionaires in a single daySpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...Behind the Markets | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sumitomo Pharma Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sumitomo Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DNPUF Stock Alerts